Prognostic Impact of IKZF1 Deletions in Association with Vincristine-dexamethasone Pulses During Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia on Trial ALL-BFM 95

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 May 23

PMID 28529312

Citations 8

Authors

L Hinze

A Moricke

M Zimmermann

S Junk

G Cario

E Dagdan

C P Kratz

V Conter

M Schrappe

M Stanulla

Affiliations

Soon will be listed here.

Citing Articles

Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.

Mullighan C, Wangondu R, Ashcraft E, Chang T, Roberts K, Brady S Res Sq. 2024; .

PMID: 39606455 PMC: 11601832. DOI: 10.21203/rs.3.rs-5292018/v1.

Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia.

Pan L, Chen Y, Weng K, Guo B, Zhuang S, Huang S BMC Cancer. 2024; 24(1):1070.

PMID: 39210321 PMC: 11363382. DOI: 10.1186/s12885-024-12828-z.

Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia.

Paolino J, Tsai H, Harris M, Pikman Y Biomedicines. 2024; 12(1).

PMID: 38255194 PMC: 10813044. DOI: 10.3390/biomedicines12010089.

Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities.

Rogers J, Gupta R, Reyes J, Gundry M, Medrano G, Guzman A Blood Adv. 2021; 5(19):3876-3890.

PMID: 34492683 PMC: 8679666. DOI: 10.1182/bloodadvances.2020002408.

Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations.

Antic Z, Yu J, van Reijmersdal S, Van Dijk A, Dekker L, Segerink W Haematologica. 2020; 106(12):3046-3055.

PMID: 33147938 PMC: 8634184. DOI: 10.3324/haematol.2020.259226.

References

Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M . Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111(9):4477-89. DOI: 10.1182/blood-2007-09-112920. View

Vrooman L, Silverman L . Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Curr Hematol Malig Rep. 2016; 11(5):385-94. DOI: 10.1007/s11899-016-0337-y. View

van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison C . IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2013; 123(11):1691-8. DOI: 10.1182/blood-2013-06-509794. View

Dorge P, Meissner B, Zimmermann M, Moricke A, Schrauder A, Bouquin J . IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2012; 98(3):428-32. PMC: 3659952. DOI: 10.3324/haematol.2011.056135. View

Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V . Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2012; 98(4):597-601. PMC: 3659991. DOI: 10.3324/haematol.2012.073965. View

Conter V, Valsecchi M, Silvestri D, Campbell M, Dibar E, Magyarosy E . Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet. 2007; 369(9556):123-31. DOI: 10.1016/S0140-6736(07)60073-7. View

Moorman A . New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2016; 101(4):407-16. PMC: 5004393. DOI: 10.3324/haematol.2015.141101. View

Conter V, Bartram C, Valsecchi M, Schrauder A, Panzer-Grumayer R, Moricke A . Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16):3206-14. DOI: 10.1182/blood-2009-10-248146. View

Mullighan C, Su X, Zhang J, Radtke I, Phillips L, Miller C . Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5):470-80. PMC: 2674612. DOI: 10.1056/NEJMoa0808253. View

10.

Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P . IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951. Leukemia. 2015; 29(11):2154-61. DOI: 10.1038/leu.2015.134. View